Btai stock forecast upward revisions have been modest

BTAI stock forecast upward revisions have been modest, yet price action suggests bullish divergence versus its 50-day moving average. Shareholders would probably be interested to learn that insiders own shares in BioXcel Therapeutics, Inc.. It has a market capitalization of just US$136m, and insiders have US$1.4m worth of shares, in their own names. It is good to see some investment by insiders, but we usually like to see higher insider holdings. It might be worth checking if those insiders have been buying. © 2020-2025 StockTitan.net - Your Edge is Information Such forecasts assume positive momentum in FDA discussions for its lead compound.